Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) EBIT: 2010-2024

Historic EBIT for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to -$4.6 million.

  • China Pharma Holdings' EBIT rose 42.12% to -$628,145 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 29.33%. This contributed to the annual value of -$4.6 million for FY2024, which is 66.76% down from last year.
  • China Pharma Holdings' EBIT amounted to -$4.6 million in FY2024, which was down 66.76% from -$2.8 million recorded in FY2023.
  • China Pharma Holdings' EBIT's 5-year high stood at -$2.6 million during FY2020, with a 5-year trough of -$4.6 million in FY2024.
  • Moreover, its 3-year median value for EBIT was -$3.5 million (2022), whereas its average is -$3.6 million.
  • In the last 5 years, China Pharma Holdings' EBIT surged by 87.37% in 2020 and then plummeted by 66.76% in 2024.
  • Yearly analysis of 5 years shows China Pharma Holdings' EBIT stood at -$2.6 million in 2020, then dropped by 10.95% to -$2.9 million in 2021, then declined by 24.07% to -$3.5 million in 2022, then grew by 22.46% to -$2.8 million in 2023, then slumped by 66.76% to -$4.6 million in 2024.